Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ENDRA Life Sciences (NDRA) Assets (2016 - 2025)

ENDRA Life Sciences has reported Assets over the past 6 years, most recently at $12.9 million for Q4 2021.

  • Quarterly Assets rose 46.89% to $12.9 million in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $12.9 million through Dec 2021, up 46.89% year-over-year, with the annual reading at $12.9 million for FY2021, 46.89% up from the prior year.
  • Assets was $12.9 million for Q4 2021 at ENDRA Life Sciences, down from $15.3 million in the prior quarter.
  • Over five years, Assets peaked at $18.9 million in Q1 2021 and troughed at $545126.0 in Q1 2017.
  • The 5-year median for Assets is $5.7 million (2017), against an average of $7.1 million.
  • Year-over-year, Assets soared 1147.8% in 2017 and then crashed 82.73% in 2018.
  • A 5-year view of Assets shows it stood at $6.1 million in 2017, then rose by 17.95% to $7.2 million in 2018, then fell by 0.64% to $7.2 million in 2019, then rose by 22.14% to $8.8 million in 2020, then surged by 46.89% to $12.9 million in 2021.
  • Per Business Quant, the three most recent readings for NDRA's Assets are $12.9 million (Q4 2021), $15.3 million (Q3 2021), and $17.2 million (Q2 2021).